Elicio Therapeutics Inc. (NASDAQ: ELTX) announced that its Phase 2 AMPLIFY-7P study of ELI-002 7P did not meet its primary ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE